Clinical Trials Browser

Carcinoma, Transitional Cell × disitamab vedotin × 90 days × Clear all

NCT04879329 2026-01-07

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Phase 2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell